142 related articles for article (PubMed ID: 35853497)
1. Rac1 as a therapeutic anticancer target: Promises and limitations.
Bailly C; Beignet J; Loirand G; Sauzeau V
Biochem Pharmacol; 2022 Sep; 203():115180. PubMed ID: 35853497
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma.
Sauzeau V; Beignet J; Vergoten G; Bailly C
Pharmacol Res; 2022 May; 179():106220. PubMed ID: 35405309
[TBL] [Abstract][Full Text] [Related]
3. Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases.
Carrizzo A; Forte M; Lembo M; Formisano L; Puca AA; Vecchione C
Curr Drug Targets; 2014; 15(13):1231-46. PubMed ID: 25345393
[TBL] [Abstract][Full Text] [Related]
4. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Guo Y; Kenney SR; Muller CY; Adams S; Rutledge T; Romero E; Murray-Krezan C; Prekeris R; Sklar LA; Hudson LG; Wandinger-Ness A
Mol Cancer Ther; 2015 Oct; 14(10):2215-27. PubMed ID: 26206334
[TBL] [Abstract][Full Text] [Related]
5. Implication of Rac1 GTPase in molecular and cellular mitochondrial functions.
Bailly C; Degand C; Laine W; Sauzeau V; Kluza J
Life Sci; 2024 Apr; 342():122510. PubMed ID: 38387701
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of small molecule Rac1 inhibitors.
Arnst JL; Hein AL; Taylor MA; Palermo NY; Contreras JI; Sonawane YA; Wahl AO; Ouellette MM; Natarajan A; Yan Y
Oncotarget; 2017 May; 8(21):34586-34600. PubMed ID: 28410221
[TBL] [Abstract][Full Text] [Related]
7. Silencing Ras-Related C3 Botulinum Toxin Substrate 1 Inhibits Growth and Migration of Hypopharyngeal Squamous Cell Carcinoma via the P38 Mitogen-Activated Protein Kinase Signaling Pathway.
Cheng H; Wang W; Wang G; Wang A; Du L; Lou W
Med Sci Monit; 2018 Feb; 24():768-781. PubMed ID: 29410394
[TBL] [Abstract][Full Text] [Related]
8. The Ins and Outs of Small GTPase Rac1 in the Vasculature.
Marinković G; Heemskerk N; van Buul JD; de Waard V
J Pharmacol Exp Ther; 2015 Aug; 354(2):91-102. PubMed ID: 26036474
[TBL] [Abstract][Full Text] [Related]
9. Stress-Sensitive Protein Rac1 and Its Involvement in Neurodevelopmental Disorders.
Wang X; Liu D; Wei F; Li Y; Wang X; Li L; Wang G; Zhang S; Zhang L
Neural Plast; 2020; 2020():8894372. PubMed ID: 33299404
[TBL] [Abstract][Full Text] [Related]
10. Identification of potent and novel inhibitors against RAC1: a Rho family GTPase.
Madhukar G; Subbarao N
In Silico Pharmacol; 2022; 10(1):13. PubMed ID: 35928028
[TBL] [Abstract][Full Text] [Related]
11. Glucotoxicity promotes aberrant activation and mislocalization of Ras-related C3 botulinum toxin substrate 1 [Rac1] and metabolic dysfunction in pancreatic islet β-cells: reversal of such metabolic defects by metformin.
Baidwan S; Chekuri A; Hynds DL; Kowluru A
Apoptosis; 2017 Nov; 22(11):1380-1393. PubMed ID: 28828705
[TBL] [Abstract][Full Text] [Related]
12. The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells.
Lucato CM; Halls ML; Ooms LM; Liu HJ; Mitchell CA; Whisstock JC; Ellisdon AM
J Biol Chem; 2015 Aug; 290(34):20827-20840. PubMed ID: 26112412
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic Roles of Calmodulin in the Regulation of KRas and Rac1 GTPases: Functional Diversity in Health and Disease.
Tebar F; Chavero A; Agell N; Lu A; Rentero C; Enrich C; Grewal T
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456244
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases.
Zhu Y; Casey PJ; Kumar AP; Pervaiz S
Cell Death Dis; 2013 Apr; 4(4):e568. PubMed ID: 23559002
[TBL] [Abstract][Full Text] [Related]
15. Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.
Cuadrado A; Martín-Moldes Z; Ye J; Lastres-Becker I
J Biol Chem; 2014 May; 289(22):15244-58. PubMed ID: 24759106
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of RAC1 in treating lung cancer patients.
Zou T; Mao X; Yin J; Li X; Chen J; Zhu T; Li Q; Zhou H; Liu Z
Clin Genet; 2017 Apr; 91(4):520-528. PubMed ID: 27790713
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor receptor-α and Ras-related C3 botulinum toxin substrate-1 regulate mechano-responsiveness of lung fibroblasts.
McGowan SE; McCoy DM
Am J Physiol Lung Cell Mol Physiol; 2017 Dec; 313(6):L1174-L1187. PubMed ID: 28775097
[TBL] [Abstract][Full Text] [Related]
18. Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity.
van der Burgh R; Pervolaraki K; Turkenburg M; Waterham HR; Frenkel J; Boes M
J Biol Chem; 2014 Oct; 289(40):27757-65. PubMed ID: 25107911
[TBL] [Abstract][Full Text] [Related]
19. Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.
Sauzeau V; Beignet J; Bailly C
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740379
[TBL] [Abstract][Full Text] [Related]
20. shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.
Huang YS; Jie N; Zhang YX; Zou KJ; Weng Y
Int J Mol Med; 2018 Mar; 41(3):1397-1408. PubMed ID: 29286138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
